Novo Nordisk falls after Reuters report of Hims launching Wegovy pill copy

Hims

05/02/2026 14:49

Updates

** Shares of Danish drugmaker Novo Nordisk NOVOb.CO fall as Reuters reports that Hims and Hers Health HIMS.N is launching copies of Novo's Wegovy pill at an introductory price of $49 per month

** Novo Nordisk's Denmark-listed shares down 7% at 283 Danish crowns; U.S. shares NVO.N fall 3.9%

** Hims says its compounded pill uses semaglutide, the same active ingredient as Wegovy, and will cost $99 a month after an initial payment, compared with Novo's $199

** Hims and Hers shares jump 10%

** Novo's obesity rival Eli Lilly LLY.N down 5%

** Novo last year ended a partnership with Hims and has raised safety and marketing concerns about compounded Wegovy copies

** Earlier this week, Novo forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market

** Novo shares down ~42% in 2025

 (Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))